angiotensin ii has been researched along with diosmin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khalil, RA; Raffetto, JD | 1 |
| Ali, FEM; Bakr, AG; El-Bahrawy, AH; Taha, HH | 1 |
2 other study(ies) available for angiotensin ii and diosmin
| Article | Year |
|---|---|
Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.
Topics: Adrenergic alpha-1 Receptor Agonists; Angiotensin II; Animals; Calcium Signaling; Diosmin; Dose-Response Relationship, Drug; Escin; In Vitro Techniques; Male; Membrane Potentials; Muscle, Smooth, Vascular; Phenylephrine; Potassium Chloride; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Varicose Veins; Vasoconstriction; Vasoconstrictor Agents; Vena Cava, Inferior | 2011 |
Diosmin enhances the anti-angiogenic activity of sildenafil and pentoxifylline against hepatopulmonary syndrome via regulation of TNF-α/VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Diosmin; Drug Synergism; Fibroblast Growth Factor 1; Hepatopulmonary Syndrome; Insulin-Like Growth Factor I; Male; Pentoxifylline; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Sildenafil Citrate; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2020 |